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ABSTRACT 
Accumulation of advanced glycation end products (AGEs) leads to various diseases such as 
diabetic complications and arteriosclerosis. In this study, we examined the effect of 
pomegranate fruit extract (PFE) and its constituent polyphenols on AGEs formation in vivo 
and in vitro. PFE, fed with a high-fat and high-sucrose (HFS) diet to KK-Ay mice, 
significantly reduced glycation products such as glycoalbumin (22.0 ± 2.4%), hemoglobin 
A1c (5.84 ± 0.23%), and serum AGEs (8.22 ± 0.17 µg/mL), as compared to a control HFS 
group (30.6 ± 2.6%, 7.45 ± 0.12% and 9.55 ± 0.17 µg/mL, respectively, P < 0.05). In 
anti-glycation assays, PFE, punicalin, punicalagin, ellagic acid, and gallic acid suppressed the 
formation of AGEs from bovine serum albumin and sugars. In this study, we discuss the 
mechanism of the anti-glycation effects of PFE and its components in vivo and in vitro. 
 
Key words: advanced glycation end products (AGEs), pomegranate, ellagic acid, punicalagin, 
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INTRODUCTION 
Glycation is a non-enzymatic multistage reaction starting with the binding of a protein and a 
reducing sugar such as glucose and fructose.1–3 In the first stage of the reaction, a Schiff base 
is generated between an amino group of the protein and the carbonyl group of the sugar, 
producing an Amadori compound such as glycoalbumin and hemoglobin A1c (HbA1c). In the 
latter stages, the Amadori compound is oxidized, dehydrated, and condensed to finally 
generate advanced glycation end products (AGEs).1,2 Some AGEs formed from a carbonyl 
compound such as glyceraldehyde and methylglyoxal are not generated through Amadori 
compounds.4 AGEs are thought to be induced by aging and hyperglycemia. The resulting 
AGEs accumulation itself accelerates aging and causes diabetic complications in which 
protein denaturation, inflammation, and oxidative stress occur.5 There are three ways to 
suppress the adverse effect of AGEs: (1) inhibition of AGEs generation, (2) degradation of 
the generated AGEs, and (3) inhibition of binding of AGEs to their receptors.1,6,7 
Several studies have reported that polyphenolic compounds inhibit the formation of 
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AGEs, by inhibiting glycation reactions.8,9 Pomegranate (Punica granatum L.) is a deciduous 
shrub of the Lythraceae family that contains various polyphenols such as ellagic acid (EA), 
punicalin (PC), and punicalagin (PG) within its fruit (Figure 1).10 Some in vitro studies 
showed that pomegranate extract and EA inhibited AGEs formation in a glycation assay using 
bovine serum albumin (BSA) and glucose.11–13 However, there are no in vivo studies designed 
to clarify whether the intake of pomegranate inhibits AGEs formation. In this study, we 
examined the effect of pomegranate fruit extract (PFE) intake on AGEs formation in the 
blood of type 2 diabetic model mice. Moreover, we compared the inhibitory effects of 
pomegranate-derived polyphenols on AGEs formation in vitro. 
 
MATERIALS AND METHODS 
Chemicals 
PFE was prepared by drying the polyphenol fraction of Indian pomegranate fruits. Briefly, 
the juice from the fruits was passed through a synthetic resin to adsorb polyphenols. Then, 
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the resin was extracted by hydrous ethanol and the extract was dried to afford the PFE 
powder. The polyphenol contents of the PFE were determined by an HPLC method according 
to Zhang, Y. et al.14 The contents of gallic acid (GA), EA, PC and PG were 1.0, 0.63, 2.7 and 
9.1% (w/w), respectively. PC and PG were isolated from the PFE. Glucose, fructose, EA, and 
aminoguanidine (AG) were purchased from Wako Pure Chemical Ind., Ltd. (Osaka, Japan). 
Glyceraldehyde and GA were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, 
USA). BSA was purchased from Jackson ImmunoResearch Inc. (West Grove, PA, USA).  
 
In vivo experiments 
Six-week-old male type 2 diabetic mice (KK-Ay/TAJc1) were purchased from CLEA Japan, 
Inc. (Tokyo, Japan). A Normal group (n = 12) was fed a normal diet (AIN-93G) throughout 
the experimental period. The other mice (n = 39) were fed a high-fat (28%) and high-sucrose 
(30%) diet modified from AIN-93G (HFS) for 2 weeks to induce hyperglycemia. The 
hyperglycemic mice were further bred with HFS (control, n = 13), HFS containing 1.5% PFE 
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(n = 13), and HFS containing 0.3% AG (positive control, n = 13). The PFE concentration was 
set to the maximum concentration that had not affected to the food intake in a preliminary 
experiment. In the experimental diet, PFE and AG were replaced with the cornstarch of HFS. 
The mice were housed individually at 21 ± 1°C, 40–50% humidity, and a 12:12-h light-dark 
cycle (lights on at 07:00) with free access to water and limited access to the experiment feed 
only for 16 h (18:00–10:00). Mouse weight was measured once per week. The tail vain blood 
after 10 hours of starvation was collected to measure glucose levels by the mutarotase and 
glucose oxidase assay15 (Glucose C II-Test Wako, Wako Pure Chemical Industries, Ltd.) and 
glycoalbumin concentration using the enzymatic assay16 (Lucica GA-L, Asahi Kasei Pharma 
Co., Tokyo, Japan) once every two weeks. At the end of the feeding period, whole blood was 
collected from the postcaval vein to measure HbA1c using the enzymatic assay17 
(Norudia-HbA1c kit, Sekisui Medical Co., Ltd., Tokyo, Japan), serum AGEs using the ELISA 
assay (Rat/mouse Glyceraldehyde-derived AGEs ELISA Kit, Up Well Co. Ltd., Fukuoka, 
Japan) and lipid peroxide using the thiobarbituric acid reactive substances assay18 (Oxiselect 
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TBARS Assay Kit, Cell Biolabs, Inc., San Diego, USA) according to the manufacturer’s 
instructions. The present study was conducted in accordance with the Animal Experiment 
Guidelines of Josai University. 
 
In vitro experiments 
BSA (50 mg/mL) and sugar (100 mM glucose, 100 mM fructose and 10 mM glyceraldehyde) 
were dissolved in 0.2 M phosphate buffer (pH 7.4). Each PFE-related sample was added to 
this solution to final concentrations of 10, 100, and 1000 µg/mL for PFE, and 10, 100, and 
1000 µM for GA, EA, PC, and PG. The non-supplemented BSA + sugar solution was used as 
a control. The mixture was incubated at 37°C in total darkness: 15 days for the 
glucose-containing mixture, 5 days for the fructose-containing mixture, and 1 day for the 
glyceraldehyde-containing mixture. After incubation, the mixture was transferred to a 96-well 
black plate (Greiner Bio-One, Tokyo, Japan) to measure the fluorescence intensity (excitation 
= 370 nm, emission = 440 nm) using Spectra Max M2 (Molecular Devices, Sunnyvale, CA, 
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USA). The rate of AGES formation was calculated as follows: 
𝐴𝐴𝐴𝐴𝐴𝐴 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑓𝑓𝑓𝑓𝑓𝑓𝑟𝑟 (%) =
𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑖𝑖𝑓𝑓𝑖𝑖𝑓𝑓𝑓𝑓𝑓𝑓𝑖𝑖𝑖𝑖𝑖𝑖 𝑓𝑓𝑓𝑓 𝑓𝑓𝑠𝑠𝑠𝑠𝑠𝑠𝑓𝑓𝑓𝑓 (𝑠𝑠𝑓𝑓𝑖𝑖𝑓𝑓𝑓𝑓 𝑖𝑖𝑓𝑓𝑓𝑓𝑓𝑓𝑖𝑖𝑠𝑠𝑖𝑖𝑖𝑖𝑓𝑓𝑓𝑓−𝑖𝑖𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑖𝑖𝑓𝑓𝑓𝑓𝑓𝑓𝑖𝑖𝑠𝑠𝑖𝑖𝑖𝑖𝑓𝑓𝑓𝑓)
𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑖𝑖𝑓𝑓𝑖𝑖𝑓𝑓𝑓𝑓𝑓𝑓𝑖𝑖𝑖𝑖𝑖𝑖 𝑓𝑓𝑓𝑓 𝑓𝑓𝑓𝑓𝑓𝑓𝑖𝑖𝑓𝑓𝑓𝑓𝑓𝑓 (𝑠𝑠𝑓𝑓𝑖𝑖𝑓𝑓𝑓𝑓 𝑖𝑖𝑓𝑓𝑓𝑓𝑓𝑓𝑖𝑖𝑠𝑠𝑖𝑖𝑖𝑖𝑓𝑓𝑓𝑓−𝑖𝑖𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑖𝑖𝑓𝑓𝑓𝑓𝑓𝑓𝑖𝑖𝑠𝑠𝑖𝑖𝑖𝑖𝑓𝑓𝑓𝑓) ∗ 100  
 
Statistical analysis 
Statistical analysis was performed with StatMate III software (ATMS Co., Ltd., Tokyo, 
Japan). The data were analyzed by Dunnett's test and Tukey's test. Differences were 
considered significant at p < 0.05. The data are expressed as means ± SE. 
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RESULTS 
Food intake and body weight 
To evaluate the anti-glycation effect of PFE in vivo, glycation markers such as glycoalbumin, 
HbA1c, and serum AGEs of KK-Ay mice fed the sample (PFE with HFS) diet for 8 weeks 
after induction of hyperglycemia were analyzed. Table 1 shows total caloric intake and total 
food intake during the experimental diet, and body weight at the end of the experiment. 
Although the amount of food intake during the sample feeding was significantly lower in 
HFS-based groups (HFS, PFE, and AG) than the Normal group, the total calorie consumption 
of all groups was virtually identical. The net intake of PFE was calculated as 1.5 mg/ g/ day. 
Final body weight was significantly higher in the HFS based-groups than in the Normal 
group. There were no differences in caloric intake and weight gain between the HFS groups. 
 
Blood glucose, glycation products, and lipid peroxide levels 
The fasting blood glucose concentration was consistently higher in the HFS-based groups 
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than in the Normal group (Figure 2). Although the glycoalbumin levels of the HFS group 
tended to be higher than those of Normal group, feeding of PFE and AG with HFS 
significantly decreased those levels after 4 and 6 weeks, respectively (Figure 3A). PFE also 
significantly reduced HbA1c levels at 8 weeks as well as AG (Figure 3B). Serum AGEs 
concentration showed a trend similar to that of glycoalbumin and HbA1c (Figure 3C). 
Among significant increases in serum lipid peroxide in all HFS-based groups, PFE slightly 
suppressed the level as compared to HFS (p = 0.059) (Figure 4). 
 
In vitro experiments 
The AGEs formation derived from BSA with glucose, fructose, and glyceraldehyde in vitro 
was concentration-dependently suppressed by addition of PFE and its components (Figure 
5A–C). An even lower concentration of PFE (10 µg/mL) significantly suppressed the AGEs 
formation from fructose and glyceraldehyde (Figure 5A). The anti-AGEs-formation potency 
of the PFE components was similar in the assays using different sugars. The potency of EA 
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and GA was comparable to that of AG. PC and PG showed higher potency than EA and GA. 
The lowest concentration of PC and PG (10 µM) remarkably inhibited the AGEs formation, 
especially with fructose (Figure 5B).  
 
DISCUSSION 
Most reports concerning the anti-glycation effect of PFE have been performed in vitro, in 
which the suppression of AGEs formation was via inhibition of the binding of proteins with 
sugars.11–13 However, it has been unclear precisely what components of pomegranate 
contribute to this suppression. Only one in vivo study reported that PFE inhibited 
collagen-derived AGEs in humans.19 However, there has been no investigation about the 
anti-glycation effects of pomegranate in vivo. Therefore, we have evaluated the anti-glycation 
effects of pomegranate in type 2 diabetes model mice, in which it is relatively easy to induce 
conditions that promote glycation. Additionally, the effect of the individual components of 
PFE was investigated by an anti-glycation in vitro assay. The results indicate that 
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pomegranate contains several components that have the ability to suppress AGEs formation 
in type 2 diabetic mice. Oral administration of PFE might not affect glucose absorption from 
meals in the intestine because there were no significant differences in caloric intake and body 
weight gain between HFS and HFS plus PFE. Higher levels of the fasting blood glucose 
concentration in the HFS plus PFE group indicate that PFE could not completely reverse the 
hyperglycemia. Therefore, the PFE-mediated reduction in HbA1c and glycoalbumin might be 
caused by inhibition of the reaction between the protein and glucose, that is, glycation. The 
accumulation of glycated albumin already started to decrease at 4 weeks after oral 
administration of PFE, also suggesting that PFE inhibited the early stages of glycation. The 
suppression of HbA1c by PFE also supports our hypothesis. The decreased accumulation of 
these glycation products probably resulted in the lower concentration of AGEs in PFE-fed 
mice. The additional benefit of PFE could be antioxidant effects that were observed as a 
slight decline in blood lipid peroxide levels. PFE and its constituent polyphenols have shown 
in vitro anti-glycation effects as evaluated by the formation of glucose- and fructose-derived 
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AGEs.20,21 In this study, we revealed that PFE and its component polyphenols suppressed the 
generation of glyceraldehyde-derived AGEs in vitro, especially the ellagitannins PC and PG 
comparable to the anti-glycation therapeutic aminoguanidine. Glyceraldehyde more easily 
reacts with protein than fructose and glucose,2,22 and the glyceraldehyde-derived AGEs are 
thought to be highly toxic.4 The anti-AGEs-formation potency seemed to depend on the 
number of phenolic groups, suggesting that these polyphenols acted as an antioxidant in the 
latter stages of glycation in vitro. However, orally administered ellagitannins hardly transfer 
to the blood because of their relatively high molecular weight.23–25 Ellagitannins like PC and 
PG are digested by gastric acid to EA some of which will appear in the blood. The rest of EA 
is metabolized by intestinal bacteria into urolithin which also will appear in the 
blood.23,24,26,27  
Liu, W. et al. Reported that urolithin possessed anti-glycation effect similar to 
aminoguanidhine.13 Therefore, the anti-glycation effect of PFE shown in this in vivo study 
might be induced by these metabolites that had been degraded from ellagitannins in the 
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digestive tract. Additionally, ellagitannins might contribute to the inhibition of exogenous 
AGEs formation in the gastrointestinal tract. Further study is needed to clarify the mechanism 
of how the metabolites incorporated into the blood inhibit early stages of glycation. 
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 Figure Captions 
Figure 1. Structures of pomegranate polyphenols. 
 
Figure 2. Fasting serum glucose levels in diabetic model mice fed with Normal (n=11-12), 
HFS (n=12-13), HFS+PFE (n=12-13), and HFS+AG (n=11-13) diets. Data are shown as the 
means ± SE. (n = 10–13), Tukey’s test p < 0.05. 
 
Figure 3. Serum glycation markers of (A) glycoalbumin levels (n=11-13) at 4, 6 and 8 weeks, 
(B) hbA1c levels (n=11-13) at 8 weeks, and (C) serum AGEs (n=4) at 8 weeks in diabetic 
model mice fed normal, HFS, HFS+PFE, and HFS+AG diets. Data are shown as the means ± 
S.E., Tukey’s test p < 0.05.  
 
Figure 4. Serum lipid peroxide in diabetic model mice fed normal, HFS, HFS+PFE, and 
HFS+AG diets. Data are shown as the means ± SE. (n = 10), Tukey’s test p < 0.05. 
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Figure 5. Anti-glycation effects of PFE and its polyphenols on (A) glucose-derived, (B) 
fructose-derived, and (C) glyceraldehyde-derived AGEs formation. Data are shown as the 
means ± SE. (n = 3), Dunnett’s test, *p < 0.05, **p < 0.01.
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Table 1. Total food intake, total caloric intake and final body weight of diabetic model mice 
fed with normal (n=13), HFS (n=13), HFS+PFE (n=13), and HFS+AG (n=13) diets. Data are 
shown as the means ± SE. Tukey’s test p < 0.05. 
 
Parameter Normal HFS HFS+PFE HFS+AG 
Total calorie intakes (kcal) 1262 ± 18 a  1240 ± 25 a 1220 ± 27 a  1266 ± 40 a  
Total food intakes (g) 318 ± 4.5 a 241 ± 4.9 b 240 ± 5.2 b 247 ± 7.7 b 
Body weight (g) 44.9 ± 0.76 a 48.6 ± 0.92 b 49.6 ± 1.1 b 49.3 ± 1.4 b 
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 Figure 1. 
ellagic acid punicalin punicalagin 
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Figure 2. 
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 Figure 3. 
B) HbA1c level 
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Figure 4.
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 Figure 5. 
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